Media Pack
News

Current Edition

Volume 7 issue 1

Upcoming Events

 
 

Advertisement

 
news

Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs

Pfizer has agreed to acquire Biohaven Pharmaceuticals for $11.6 billion in a deal that turns an existing alliance on a fast-selling migraine drug into a big bet on it...
13 May 2022 news Biohaven | Drugs
Continue Reading →
news

Biohaven to seek FDA approval for second migraine drug after study success

While a smaller biotech company, Biohaven has succeeded in a market led by large pharmaceutical firms like Lilly, AbbVie and, in the preventive treatment setting, Amg...
10 December 2021 news ABBVIE | Amgen
Continue Reading →
news

Pfizer buys into Biohaven’s fast-selling migraine medicine

Faced with breaking into markets led by larger companies, Biohaven turned to celebrity endorsements, Tiktok and racecar advertising to aggressively sell Nurtec ODT. I...
15 November 2021 news Biohaven | migraine
Continue Reading →
news

Biohaven’s pipeline takes a hit as drug for rare neurological disease falls short in trial

Biohaven has built itself into a nearly $10 billion company on the strength of its migraine drug Nurtec, which surprised Wall Street with second-quarter sales that we...
30 September 2021 news ABBVIE | Amgen
Continue Reading →
 
IBI-white.png

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Facebook Linkedin
Bio Pharmaceutical Media © 2024, All Rights Reserved – Powered by Teksyte